Evommune
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Evommune sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Evommune: 5 sponsored US clinical trials, 3 recruiting.
Evommune sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Spontaneous Urticaria, with 1 trials.
Upper-quartile sponsor footprint
Evommune sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Study of EVO756 in Adults With Migraine
NCT07616128
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT07150845
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
NCT06873516
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
NCT06603220
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
NCT05579899
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Therapeutic Areas
What is open in the Evommune pipeline
3 recruiting of 5 indexed (60% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Chronic Spontaneous Urticaria (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Evommune: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Evommune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Beam Therapeutics · 60% recruiting · 5 trials
Related
What to do with this Evommune page
5 registered trials is a research-attention snapshot, not an endorsement of Evommune or any single study.
- 3 of Evommune's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Spontaneous Urticaria is the condition Evommune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Spontaneous Urticaria trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Evommune pipeline card: 5 registered trials from official public datasets.Report a data error.